SCYNEXIS INC
SCYXNasdaq
$4.27
↓ -4.7%Jul 17 close · end-of-day
Price
1Y↓ -29.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$217.6M
Enterprise Value
$158.3M
P/E
—
P/S
10.7
P/B
5.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$20.3M
Net Income (TTM)
-$24.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-120.0%
Net Margin
-120.5%
ROE
-59.4%
ROIC
—
Debt / Equity
—
Net Cash
$59.3M
Return 1Y
-27.9%
Company profile
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.
- CEO
- Marco Taglietti
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- New Jersey
- Website
- scynexis.com
Management & directors
- Angulo Gonzalez DavidChief Executive Officer
- Macleod IvorChief Financial Officer
- Sukenick ScottChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
SCYX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.42↑ +281.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $13.2M | $5.1M | $140.1M | $3.7M | $20.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$51.1M | -$60.8M | -$85.8M | $72.7M | -$37.1M | -$16.1M |
| Net income | -$55.2M | -$32.9M | -$62.8M | $67.0M | -$21.3M | -$8.6M |
| Diluted EPS | — | -$1.25 | -$1.47 | $1.39 | -$0.44 | -$0.17 |
| Operating cash flow | -$49.4M | -$54.6M | -$79.9M | $60.2M | -$24.0M | -$5.3M |
| Free cash flow | -$49.4M | -$54.6M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -462.2% | -1684.5% | 51.9% | -990.8% | -78.0% |
| Net margin | — | -249.7% | -1233.7% | 47.8% | -568.3% | -41.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $736,000.00 | $660,000.00 | $977,000.00 | $257,000.00 | $1.4M | $334,000.00 | $18.6M | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.2M | -$10.3M | -$8.1M | -$8.6M | -$9.6M | -$8.4M | $10.5M | -$16.9M |
| Net income | -$14.5M | -$2.8M | -$4.4M | -$5.4M | -$6.9M | -$8.6M | $12.3M | -$21.3M |
| Diluted EPS | -$0.30 | -$0.06 | -$0.09 | -$0.11 | -$0.14 | -$0.17 | $0.25 | -$0.42 |
| Operating cash flow | -$10.9M | $765,000.00 | -$9.9M | -$7.5M | -$7.5M | -$8.7M | $18.4M | -$8.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1255.0% | -1563.6% | -824.2% | -3350.2% | -701.0% | -2516.5% | 56.3% | — |
| Net margin | -1964.4% | -425.5% | -453.7% | -2097.7% | -504.8% | -2572.2% | 65.7% | — |
Company news
Jun 1, 2026
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-26 | Tinmouth Brian Philippe | Award | 2,875 | $0.00 | $0.00 | filing |
| 2026-06-26 | Macdonald Guy | Award | 2,875 | $0.00 | $0.00 | filing |
| 2026-06-26 | ANIDO ARMANDO | Award | 2,875 | $0.00 | $0.00 | filing |
| 2026-06-26 | HASTINGS DAVID C | Award | 2,875 | $0.00 | $0.00 | filing |
| 2026-06-26 | HANHAM ANN | Award | 2,875 | $0.00 | $0.00 | filing |
| 2026-04-01 | Angulo Gonzalez David· Chief Executive Officer | Buy | 108,695 | — | — | filing |
| 2026-01-29 | Macleod ivor· Chief Financial Officer | Award | 129,833 | $0.00 | $0.00 | filing |
| 2026-01-29 | Sukenick Scott· Chief Legal Officer | Award | 129,833 | $0.00 | $0.00 | filing |
| 2026-01-29 | Angulo Gonzalez David· Chief Executive Officer | Award | 391,333 | $0.00 | $0.00 | filing |
| 2025-10-17 | Angulo Gonzalez David· Chief Executive Officer | Award | 32,500 | $0.76 | $24,700.00 | filing |
| 2025-06-26 | Tinmouth Brian Philippe | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-06-26 | Macdonald Guy | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-06-26 | HASTINGS DAVID C | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-06-26 | HANHAM ANN | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-06-26 | GILMAN STEVEN C | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-06-26 | ANIDO ARMANDO | Award | 23,000 | $0.00 | $0.00 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.